These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 10408550)

  • 1. A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Simon JH; Jacobs LD; Campion MK; Rudick RA; Cookfair DL; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Simonian N; Lajaunie M; Miller DE; Wende K; Martens-Davidson A; Kinkel RP; Munschauer FE; Brownscheidle CM
    Neurology; 1999 Jul; 53(1):139-48. PubMed ID: 10408550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A validation study of manual atrophy measures in patients with Multiple Sclerosis.
    Cappelle S; Pareto D; Tintoré M; Vidal-Jordana A; Alyafeai R; Alberich M; Sastre-Garriga J; Auger C; Montalban X; Rovira À
    Neuroradiology; 2020 Aug; 62(8):955-964. PubMed ID: 32246177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group.
    Simon JH; Lull J; Jacobs LD; Rudick RA; Cookfair DL; Herndon RM; Richert JR; Salazar AM; Sheeder J; Miller D; McCabe K; Serra A; Campion MK; Fischer JS; Goodkin DE; Simonian N; Lajaunie M; Wende K; Martens-Davidson A; Kinkel RP; Munschauer FE
    Neurology; 2000 Jul; 55(2):185-92. PubMed ID: 10908888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
    Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
    Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study.
    Horakova D; Cox JL; Havrdova E; Hussein S; Dolezal O; Cookfair D; Dwyer MG; Seidl Z; Bergsland N; Vaneckova M; Zivadinov R
    J Neurol Neurosurg Psychiatry; 2008 Apr; 79(4):407-14. PubMed ID: 17550987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years.
    Turner B; Lin X; Calmon G; Roberts N; Blumhardt LD
    Mult Scler; 2003 Feb; 9(1):21-7. PubMed ID: 12617263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group.
    Rudick RA; Fisher E; Lee JC; Simon J; Jacobs L
    Neurology; 1999 Nov; 53(8):1698-704. PubMed ID: 10563615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients.
    Fisher E; Rudick RA; Cutter G; Baier M; Miller D; Weinstock-Guttman B; Mass MK; Dougherty DS; Simonian NA
    Mult Scler; 2000 Dec; 6(6):373-7. PubMed ID: 11212131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis.
    Pontillo G; Cocozza S; Di Stasi M; Carotenuto A; Paolella C; Cipullo MB; Perillo T; Vola EA; Russo C; Masullo M; Moccia M; Lanzillo R; Tedeschi E; Elefante A; Brescia Morra V; Brunetti A; Quarantelli M; Petracca M
    Eur Radiol; 2020 Jul; 30(7):3813-3822. PubMed ID: 32100089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Rudick RA; Goodkin DE; Jacobs LD; Cookfair DL; Herndon RM; Richert JR; Salazar AM; Fischer JS; Granger CV; Simon JH; Alam JJ; Simonian NA; Campion MK; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Whitham RH
    Neurology; 1997 Aug; 49(2):358-63. PubMed ID: 9270562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.
    Horakova D; Dwyer MG; Havrdova E; Cox JL; Dolezal O; Bergsland N; Rimes B; Seidl Z; Vaneckova M; Zivadinov R
    J Neurol Sci; 2009 Jul; 282(1-2):112-9. PubMed ID: 19168190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.
    Rojas JI; Patrucco L; Miguez J; Besada C; Cristiano E
    Neurol Res; 2014 Jul; 36(7):615-8. PubMed ID: 24620963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the FIM instrument in a trial of intramuscular interferon beta-1a for disease progression in relapsing-remitting multiple sclerosis.
    Granger CV; Wende K; Brownscheidle CM
    Am J Phys Med Rehabil; 2003 Jun; 82(6):427-36. PubMed ID: 12820784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis.
    van den Elskamp IJ; Boden B; Dattola V; Knol DL; Filippi M; Kappos L; Fazekas F; Wagner K; Pohl C; Sandbrink R; Polman CH; Uitdehaag BM; Barkhof F
    Neuroradiology; 2010 Oct; 52(10):875-81. PubMed ID: 20049424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From enhancing lesions to brain atrophy in relapsing MS.
    Simon JH
    J Neuroimmunol; 1999 Jul; 98(1):7-15. PubMed ID: 10426356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interferon beta-1a (Avonex TM): clinical and MRI impacts].
    Vermersch P
    Rev Neurol (Paris); 1999; 155 Suppl 2():S13-9. PubMed ID: 10367320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.